Tag: time

TORONTO, July 23, 2025 /CNW/ -- As power outages become more frequent and off-grid living gains momentum across Canada, BLUETTI has launched the Apex 300,...

Basecase is for RAN to Stay Flat REDWOOD CITY, Calif., July 23, 2025 /PRNewswire/ -- According to a newly published forecast report by Dell'Oro Group,...

From New York's skyline to Shanghai's streets, hypnotic beats meet effortless style for the modern traveler SHANGHAI, July 23, 2025 /PRNewswire/ -- W Hotels, part of...

DHAKA, Bangladesh, July 23, 2025 /PRNewswire/ -- Himel, the globally acclaimed manufacturer and supplier of electric products, has officially launched in Bangladesh, igniting its presence...

NEW YORK, July 22, 2025 /PRNewswire/ -- Expert Consumers has recognized QuickBooks as a leading AI bookkeeping solution in its latest 2025 software review. The...

SINGAPORE, July 23, 2025 /PRNewswire/ -- Dr. Roy Yap, Head of the School for Business and Law at LSBF Singapore, was featured on Channel...

BEIJING, July 22, 2025 /PRNewswire/ -- Editor's Note: Chinese people believe that letters are as valuable as gold. For thousands of years, letters, across mountains...

ZUG, Switzerland, July 22, 2025 (GLOBE NEWSWIRE) -- Pharvaris N.V. (“Pharvaris,” Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), announced today the pricing of an underwritten offering of (i) 8,250,000 of its ordinary shares at a price of $20.00 per share and (ii) to one investor, pre-funded warrants to purchase 500,000 ordinary shares at a price of $19.99 per pre-funded warrant, which represents the per share public offering price for the ordinary shares less the $0.01 per share exercise price for each such pre-funded warrant. All shares and pre-funded warrants in the offering are to be sold by Pharvaris. In addition, Pharvaris has granted the underwriters a 30-day option to purchase up to an additional 1,312,500 ordinary shares at the public offering price, less underwriting discounts and commissions. The gross proceeds to Pharvaris from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $175 million, excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on or about July 24, 2025, subject to satisfaction of customary closing conditions.

NEW YORK, July 22, 2025 /PRNewswire/ -- Blazing Star Merger Sub, Inc. (the "Offeror" announced today the commencement of cash tender offers (each, an...

For the first time, fans can help bring the untold story of Jim Thorpe to the screen and honor a legacy long overdue DALLAS, July...

CUB says record-high capacity price points to urgent need to reform PJM policy, pass comprehensive energy legislation in Illinois CHICAGO, July 22, 2025 /PRNewswire/ --...

82km of drilling and $9M invested in resource development and exploration in Q4, FY25 PERTH, Western Australia, July 23, 2025 /CNW/ - Westgold Resources Limited...

ASX Release $132M Treasury Build in Q4 FY25 PERTH, Western Australia, July 23, 2025 /CNW/ - Westgold Resources Limited (ASX | TSX: WGX - Westgold or the Company) is pleased to report results...